Table of contents
June 2004 Vol 4 No 6
In this issue
p413 | doi:10.1038/nrc1379
Research Highlights
Targeted therapies: No longer in the dark
p415 | doi:10.1038/nrc1376
In the news
Through the keyhole
p416 | doi:10.1038/nrc1381
Screening: Fishing for clues
p416 | doi:10.1038/nrc1383
Pharmacodynamics: PET power
p417 | doi:10.1038/nrc1384
Trial Watch
IGF and cancer risk
p417 | doi:10.1038/nrc1386
Breast cancer: Establishing normality
p418 | doi:10.1038/nrc1377
Imaging: Glowing success
p418 | doi:10.1038/nrc1382
In brief
Metastasis | Prognostic markers | Chemosensitivity | Therapeutics
p419 | doi:10.1038/nrc1380
Tumorigenesis: RapTOR strikes again
p419 | doi:10.1038/nrc1385
Targeted therapies: Layers of necessity
p420 | doi:10.1038/nrc1373
Apoptosis: Profit and loss
p420 | doi:10.1038/nrc1375
Tumorigenesis: Right place, wrong time
p421 | doi:10.1038/nrc1374
Reviews
The anti-angiogenic basis of metronomic chemotherapy
Robert S. Kerbel & Barton A. Kamen
p423 | doi:10.1038/nrc1369
Exploiting tumour hypoxia in cancer treatment
J. Martin Brown & William R. Wilson
p437 | doi:10.1038/nrc1367
Dissecting the metastatic cascade
Klaus Pantel & Ruud H. Brakenhoff
p448 | doi:10.1038/nrc1370
The potential of positron-emission tomography to study anticancer-drug resistance
Catharine M. L West, Terry Jones & Pat Price
p457 | doi:10.1038/nrc1368
Perspectives
Opinion
Yeast as a model system for anticancer drug discovery
Julian A. Simon & Antonio Bedalov
p481 | doi:10.1038/nrc1372
Opinion
The Icelandic Cancer Project – a population-wide approach to studying cancer
Thorunn Rafnar, Steinunn Thorlacius, Eirikur Steingrimsson, Mikkel H. Schierup, Jesper N. Madsen, Violeta Calian, Bjarki J. Eldon, Thorvaldur Jonsson, Jotun Hein & Snorri S. Thorgeirsson
p488 | doi:10.1038/nrc1371
